NCCN Publishes First Guidelines for Pediatric Brain Cancer, Recommends Broad NGS Profiling
The guidelines recognize the importance of molecular profiling in diagnosing, treating, and identifying clinical trial opportunities for children with high-grade gliomas.
Kinnate Biopharma, Guardant Health Partner for Study of BRAF Mutations in Solid Tumors
Preliminary findings indicate that about half of the 6,000 patients with BRAF alteration-positive cancers harbored Class II and III alterations.
MapKure, Personalis Partner to Screen Patients for BRAF Inhibitor Trial
Personalis plans to develop a companion diagnostic to MapKure's BRAF inhibitor, BGB-3245, once biomarkers have been identified in the study.
Novellus, Tempus Partner to Enroll Patients in BRAF Inhibitor Clinical Trial Program
The Jerusalem-based drug developer is studying PLX8394 in patients with BRAF V600-mutated gliomas and solid tumors with non-V600 mutations.
Researchers showed that ctDNA levels predicted who would respond to first-line immune checkpoint inhibition but were not useful in second-line therapy.